Upgrade to SI Premium - Free Trial

Arcutis Biotherapeutics (ARQT)

25.14 +0.28 (1.13%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/28/26 *Est.)

Latest Headlines

Form 4 Arcutis Biotherapeutics, For: Aug 20 Filed by: Curran Terrie August 24, 2026 4:20 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Aug 19 Filed by: Burnett Patrick August 21, 2026 4:08 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Curran Terrie August 20, 2026 4:51 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Aug 17 Filed by: Welgus Howard G. August 19, 2026 4:57 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick August 19, 2026 4:27 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G. August 17, 2026 4:28 PM - SEC Filing Form SCHEDULE 13G Arcutis Biotherapeutics, Filed by: Polar Capital Holdings Plc August 14, 2026 6:21 AM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Aug 11 Filed by: Burnett Patrick August 13, 2026 8:07 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick August 11, 2026 5:16 PM - SEC Filing Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 7, 2026 4:00 PM - Globe NewsWire Form SCHEDULE 13G Arcutis Biotherapeutics, Filed by: STATE STREET CORP August 7, 2026 8:57 AM - SEC Filing Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $40 at Needham August 6, 2026 7:14 AM - StreetInsider Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $36 at Mizuho August 6, 2026 6:51 AM - StreetInsider Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $38 at Guggenheim August 6, 2026 6:44 AM - StreetInsider Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 7c ; Offers Guidance August 6, 2026 12:56 AM - StreetInsider Form 4 Arcutis Biotherapeutics, For: Aug 03 Filed by: Burnett Patrick August 5, 2026 9:42 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Aug 03 Filed by: Matsuda Masaru August 5, 2026 9:42 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Aug 03 Filed by: Watanabe Todd August 5, 2026 9:42 PM - SEC Filing Form 10-Q Arcutis Biotherapeutics, For: Jun 30 August 5, 2026 4:26 PM - SEC Filing Form 8-K Arcutis Biotherapeutics, For: Jul 31 August 5, 2026 4:18 PM - SEC Filing Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update August 5, 2026 4:00 PM - StreetInsider Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru August 3, 2026 5:08 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd August 3, 2026 5:07 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick August 3, 2026 5:07 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jul 15 Filed by: Peetz Christopher July 17, 2026 4:07 PM - SEC Filing Form 3 Arcutis Biotherapeutics, For: Jul 15 Filed by: Peetz Christopher July 17, 2026 4:05 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jul 15 Filed by: Welgus Howard G. July 17, 2026 4:01 PM - SEC Filing Form 8-K Arcutis Biotherapeutics, For: Jul 15 July 16, 2026 4:25 PM - SEC Filing Arcutis adds Mirum Pharmaceuticals CEO Chris Peetz to its board July 16, 2026 9:00 AM - StreetInsider Arcutis Expands Board of Directors with Appointment of Chris Peetz July 16, 2026 9:00 AM - StreetInsider Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G. July 15, 2026 4:02 PM - SEC Filing Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 July 15, 2026 4:00 PM - Globe NewsWire Attovia Therapeutics names John Smither to board of directors July 15, 2026 8:30 AM - StreetInsider Attovia Therapeutics Appoints John W. Smither to Board of Directors July 15, 2026 8:30 AM - Globe NewsWire FDA accepts Arcutis sNDA for Zoryve cream in infants as young as 3 months July 8, 2026 8:00 AM - StreetInsider FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months July 8, 2026 8:00 AM - StreetInsider Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 2, 2026 4:00 PM - Globe NewsWire Arcutis launches virtual platform linking patients to dermatologists June 30, 2026 9:17 AM - StreetInsider Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications June 30, 2026 9:15 AM - Globe NewsWire FDA approves Arcutis' roflumilast cream for plaque psoriasis in children 2+ June 29, 2026 7:06 PM - StreetInsider FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 June 29, 2026 7:06 PM - Globe NewsWire Form 4 Arcutis Biotherapeutics, For: Jun 15 Filed by: LIN SUE-JEAN June 17, 2026 8:47 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 15 Filed by: Welgus Howard G. June 17, 2026 8:40 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G. June 17, 2026 4:09 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: LIN SUE-JEAN June 15, 2026 4:12 PM - SEC Filing Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G. June 15, 2026 4:11 PM - SEC Filing Form 4/A Arcutis Biotherapeutics, For: Jun 05 Filed by: Heron Patrick J June 12, 2026 5:55 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Heron Patrick J June 9, 2026 9:22 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: LIN SUE-JEAN June 9, 2026 9:21 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Welgus Howard G. June 9, 2026 9:21 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Leonard Keith R June 9, 2026 9:21 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Curran Terrie June 9, 2026 9:21 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Munshi Amit June 9, 2026 9:21 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Gilbert Halley E June 9, 2026 9:21 PM - SEC Filing Form 4 Arcutis Biotherapeutics, For: Jun 05 Filed by: Krishnamohan Neha June 9, 2026 9:21 PM - SEC Filing Form 8-K Arcutis Biotherapeutics, For: Jun 05 June 9, 2026 4:06 PM - SEC Filing Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 5, 2026 4:00 PM - Globe NewsWire New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology June 3, 2026 8:00 AM - StreetInsider Full Article List